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ABSTRACT
Graft-versus-host-disease (GVHD) is a serious complication of allogeneic bone marrow transplantation, and donor T cells are indispensable for GVHD. Current therapies have limited efficacy, selectivity, and high toxicities. We used a novel flow cytometric technique for the analysis of intracellular phosphorylation events in single cells in murine BMT models to identify and validate novel GVHD drug targets [1] [2] [3] [4] [5] [6] [7] . This method circumvents the requirement for large numbers of purified cells, unlike western blots. We defined a signaling profile for alloactivated T cells in vivo and identified the phosphorylation of ERK1/2 and STAT-3 as important events during T cell (allo)activation in GVHD. We establish that interference with STAT-3 phosphorylation can inhibit T cell activation and proliferation in vitro and GVHD in vivo. This suggests that phospho-specific flow cytometry is useful for the identification of promising drug targets, and ERK1/2 and STAT-3 phosphorylation in alloactivated T cells may be important for
GVHD.
INTRODUCTION
Analysis of in vivo T cell signaling with Western Blots is limited by requirements for large numbers of cells and the inability to access subpopulations. We used a flow-cytometric method for measuring phosphorylated epitopes in single cells [1] [2] [3] [4] [5] [6] [7] to establish a signaling profile for alloactivated T cells in vivo in murine GVHD after allogeneic bone marrow transplantation.
We identify and validate molecular targets important for GVHD pathobiology and demonstrate the importance of ERK1/2 and STAT-3 phosphorylation for T cell alloactivation in vivo. Finally, we confirm that small molecule inhibitors of STAT-3 phosphorylation can attenuate T cell activation, proliferation, and GVHD.
MATERIALS AND METHODS
Bone marrow transplantation, transfer of CFSE-labeled T cells, and GVHD assessment were described previously 8, 9 and discussed in Supplemental Methods. In vitro stimulation of T cells with cytokines, anti-CD3, anti-CD3+CD28 antibody, or irradiated stimulator cells were previously described 1,9 and further discussed in Supplemental Methods. All protocols were approved by the IACUC of Memorial Sloan-Kettering Cancer Center.
Cell surface staining, intracellular phospho-specific staining, flow cytometry and data analysis were previously described 2,4-6 and further discussed in Supplemental Methods. The T(X) population comparison metric was described previously 10 and its use is further discussed in the Supplemental Methods. Finally, a list of phospho-specific antibodies and inhibitors used in this study can also be found in Supplemental Methods.
RESULTS AND DISCUSSION
We first validated the antibodies for this study (Supplemental Figure 1a- Figure 2) . We also determined the total levels of many signaling proteins with non-phosphorylation-specific antibodies. This revealed similar but milder trends, and effector and memory T cells contain in many cases more total protein compared to naïve cells, as reported in the literature 11 .
We stimulated splenic T cells with cytokines involved in activation and Th1 We next turned to mouse models of T cell alloactivation and GVHD. We first infused CFSE-labeled B6 T cells into irradiated syngeneic B6 CD45.1 or allogeneic C3FeB6F1 hosts. In For (Figure 1b) . Additionally, nearly all donor T cells demonstrated extensive p38 and JNK phosphorylation, potentially due to the proinflammatory cytokine environment. We also observed increased STAT-5A phosphorylation in donor T cells, which may reflect stimulation by IL-2, IL-7, and IL-15. Interestingly, STAT-1 phosphorylation (e.g. due to IFNγ) was only modestly increased, which could be due to declining IFNγ levels or downregulation of IFNγR2 on effector T cells 12 .
Having observed STAT-3 and ERK1/2 activation as prominent features of alloactivated T cells in this GVHD model, we next tested whether STAT-3 and ERK1/2 phosphorylation were required for T cell (allo)activation. We inhibited ERK 1/2 phosphorylation with SL327, a selective inhibitor of MEK 1/2, the upstream MAPKK [17] [18] [19] [20] , and STAT-3 phosphorylation with cucurbitacin E and I, compounds which target upstream Janus kinases [21] [22] [23] [24] .
We first assessed whether inhibiting ERK 1/2 phosphorylation with SL327 could attenuate the proliferation of normal B6 splenic T cells in response to anti-CD3+CD28 stimulation in vitro, and found a dose-dependent suppression of proliferation (Figure 2a) . We evaluated the toxicity of SL327 and found that T cells were not significantly apoptotic at concentrations below 100 ng/mL (not shown). We also evaluated the effects of inhibiting ERK1/2 phosphorylation in allogeneic mixed leukocyte reactions (MLRs), which are more relevant to T cell alloactivation during GVHD. SL327 again caused a dose-dependent suppression of T cell proliferation (Figure 2b) , and no significant toxicity was observed after 4 days of culture at concentrations below 50 ng / mL (not shown). This suggests that ERK1/2 phosphorylation is important for the activation or proliferation of T cells. While SL327 pharmacokinetics precluded treatment in vivo, the ERK1/2 inhibitor PD98059 is reported to attenuate murine cardiac allograft rejection, with decreased T cell IFNγ and increased IL-4
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Next we analyzed the importance of STAT
We found negligible Th17 cells, and percentages of CD44 + CD62L -effector Th1 cells were similar (data not shown).
Our results demonstrate the feasibility of phospho-specific flow cytometry for the in vivo analysis of intracellular signaling in a disease model. We detected increased ERK 1/2 and STAT-3 phosphorylation in alloreactive T cells in allo-BMT recipients with GVHD and showed that inhibiting ERK1/2 or STAT-3 activation can attenuate T cell (allo)activation and GVHD.
Development of STAT-3 or ERK 1/2 inhibitors suitable for administration in vivo could result in novel therapeutics for the prophylaxis and treatment of GVHD.
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For personal use at PENN STATE UNIVERSITY on February 28, 2013. bloodjournal.hematologylibrary.org From (f) Experiment was performed as in (a) and median fluorescence intensity of CD69 was determined. N=8 per group, combined data from four independent experiments.
(g) B6 splenocytes (6x10 7 cells) were incubated with 5 nM cucurbitacin I or control (DMSO) for 1 hour at 37 degrees C before adoptive transfer into lethally irradiated (850 cGy) BALB/c mice.
Recipients also received 5x10 6 T cell depleted B6 marrow, and were monitored and analyzed for survival, weight loss, and clinical signs of GVHD. Combined data from two independent experiments, with N=20 per group for groups receiving splenocytes.
(h-i) Mice were transplanted as in (g) and evaluated for weight loss from baseline and semiquantitative clinical GVHD scores on day six after allo-BMT (N=8 per group).
(j) Mice were transplanted and total splenic cellularity was assessed by hemacytometer on day six. Cells were analyzed by flow cytometry, and donor CD4 and CD8 T cells were defined as H- For personal use at PENN STATE UNIVERSITY on February 28, 2013. bloodjournal.hematologylibrary.org From
